Discover a trial in which patients received either IL-2 or a placebo for 5 days, followed by weekly doses for 4 weeks.

Coya sees IL-2 as a molecule that can boost the number and power of regulatory T cells (Tregs), leading it to study it as a single agent, COYA 301, and pair the cytokine with the recombinant ...

Discover a study that shows that modulating STAT6 directly may represent an innovative strategy for managing severe, ...

Another example is engineering T cells to express cytokines like IL-12, which enhances their ability to target and kill ...

Merck & Co/MSD has agreed to buy Pandion for $1.85 billion, bolting on a pipeline of drugs for autoimmune and other immunological disorders headed by interleukin-2 (IL-2) based therapy PT-101.

New research from the University of Pittsburgh uncovers how inhaled house dust mites, a common trigger of allergic asthma, ...